MAY 19, 2022 1:56 PM PDT

Experimental Drug Shows Promise Against ALS

WRITTEN BY: Annie Lennon

A new experimental drug known as NU-9 may be more effective in treating ALS than existing FDA-approved drugs. The corresponding study was published in Nature

ALS is characterized by fatal paralysis caused by the degeneration of the upper section of motor neurons known as axons, which connect the brain to the spinal cord. For a drug to be effective against ALS, it must thus improve axon outgrowth and health. 

In research published last year, scientists found that NU-9 improved two critical factors that lead to ALS in upper motor neurons: protein misfolding and protein aggregation in cells. They further found that neurons in mouse models resembled healthy controls after 60 days of treatment with NU-9. 

In the present study, the researchers tested NU-9 on mouse models of ALS again, both in combination with FDA-approved drugs for ALS - riluzole or edaravone, and by itself. They also compared these results to mice treated exclusively with these pre-existing drugs.

In doing so, the researchers found that NU-9 was able to lengthen axons in diseased upper motor neurons in mice. They also found that its therapeutic effects were stronger than those of existing FDA-approved drugs when taken alone. However, they noted that a combination treatment of NU-9 and either pre-existing drug produced the most significant results. 

NU-9 is now undergoing animal safety studies to determine dose levels and toxic effects in preparation for clinical trials. Should these prove successful, the researchers hope to start Phase 1 clinical trials in early 2023. 

"It is a long process - possibly 10 to 12 years - to discover and bring a new drug to the market," said Richard B. Silverman, the Patrick G. Ryan/Aon Professor at Northwestern University, and one of the study’s authors, "But this drug has us very excited and hopeful about its possibilities to improve the lives of ALS patients, who have been without hope for so long."


Sources: Nature, Science Daily

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
MAY 20, 2022
Drug Discovery & Development
Drug Shows Promise in treating Spinal Cord Injury
MAY 20, 2022
Drug Shows Promise in treating Spinal Cord Injury
A drug developed by AstraZeneca preserves 80% of nerve function following spinal cord compression injury. The correspond ...
JUN 06, 2022
Drug Discovery & Development
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
JUN 06, 2022
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
A new class of antibiotics has shown promise in preclinical trials against drug-resistant tuberculosis. The correspondin ...
JUL 08, 2022
Cannabis Sciences
The Latest Research on Cannabis Social Equity Programs
JUL 08, 2022
The Latest Research on Cannabis Social Equity Programs
Cannabis social equity programs are designed to increase licensure and employment opportunities for lower income and BIP ...
JUL 05, 2022
Immunology
A New Type of Universal Flu Vaccine
JUL 05, 2022
A New Type of Universal Flu Vaccine
Researchers have created a new 'universal' flu vaccine, which is directed against type A influenza viruses. It w ...
JUL 21, 2022
Cancer
Can Microrobots Deliver Chemotherapy Directly to a Tumor?
JUL 21, 2022
Can Microrobots Deliver Chemotherapy Directly to a Tumor?
Microrobotics, also called microbotics, is a field of study focusing on miniature robotics capable of carrying tiny comp ...
JUL 23, 2022
Drug Discovery & Development
Anti-inflammatory Compound Shows Promise in Treating Severe COVID-19
JUL 23, 2022
Anti-inflammatory Compound Shows Promise in Treating Severe COVID-19
An anti-inflammatory compound has shown promise in treating systemic inflammation and brain injury in patients with seve ...
Loading Comments...